Danaher Co. (NYSE:DHR) CEO Thomas Patrick Joyce, Jr. sold 181,394 shares of the company’s stock in a transaction on Friday, July 24th. The stock was sold at an average price of $193.98, for a total value of $35,186,808.12. Following the sale, the chief executive officer now owns 285,569 shares of the company’s stock, valued at approximately $55,394,674.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE:DHR opened at $202.14 on Friday. Danaher Co. has a one year low of $119.60 and a one year high of $204.13. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.74 and a current ratio of 2.20. The firm has a market cap of $141.34 billion, a price-to-earnings ratio of 43.28, a PEG ratio of 3.19 and a beta of 0.92. The firm’s fifty day moving average is $181.65 and its two-hundred day moving average is $161.73.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, beating the consensus estimate of $1.09 by $0.35. Danaher had a net margin of 17.73% and a return on equity of 11.88%. The company had revenue of $5.30 billion for the quarter, compared to analyst estimates of $5.01 billion. During the same period in the prior year, the company earned $1.09 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. As a group, equities research analysts predict that Danaher Co. will post 5.36 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $203.00 price target on the stock in a research report on Tuesday, July 21st. Wells Fargo & Co upped their target price on Danaher from $155.00 to $170.00 and gave the company an “overweight” rating in a research report on Tuesday, April 21st. Needham & Company LLC upped their target price on Danaher from $183.00 to $209.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank of Canada upped their target price on Danaher from $205.00 to $218.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Citigroup upped their target price on Danaher from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $197.73.
Hedge funds have recently bought and sold shares of the company. Lion Street Advisors LLC purchased a new stake in shares of Danaher during the 1st quarter worth about $25,000. Archer Investment Corp purchased a new stake in shares of Danaher during the 4th quarter worth about $27,000. Howe & Rusling Inc. boosted its stake in shares of Danaher by 81.4% during the 2nd quarter. Howe & Rusling Inc. now owns 156 shares of the conglomerate’s stock worth $28,000 after acquiring an additional 70 shares in the last quarter. Manchester Financial Inc. lifted its stake in Danaher by 50.0% in the 1st quarter. Manchester Financial Inc. now owns 228 shares of the conglomerate’s stock valued at $32,000 after buying an additional 76 shares in the last quarter. Finally, Semmax Financial Advisors Inc. purchased a new position in Danaher in the 2nd quarter valued at about $35,000. 77.67% of the stock is currently owned by institutional investors and hedge funds.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Most Active Stocks: Dollar Volume vs Share Volume
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.